The 9 influenza vaccines available for the upcoming respiratory virus season come from 4 manufacturers in single-dose syringes and vials and multidose vials may still be available.
The CDC and the Advisory Committee on Immunization Practices (ACIP) continue to recommend annual influenza vaccination for all individuals aged 6 months and older, except in rare cases of contraindication. This includes all children, adults, and pregnant women.
For the 2025–2026 season, all US influenza vaccines are trivalent, covering 2 type A strains and 1 type B strain, according to the CDC. Based on recommendations made during the June meeting of the ACIP, the CDC advises use of single-dose, thimerosal-free formulations this season for all populations. Multidose vials containing the mercury-based preservative are no longer recommended and availability is expected to vary by manufacturer.
There are no preferential recommendations made between vaccine types for most individuals. For adults aged 65 years and older, however, the preferred influenza vaccines are high-dose, inactivated, recombinant or adjuvanted inactivated formulations whenever they are available.
Pediatric Dosing. Children aged 6 months to 8 years who are receiving influenza vaccine for the first time (or with unknown prior vaccination history) should be given 2 doses at least 4 weeks apart.
The short slide show above is a quick look at the 9 influenza vaccine products available for the upcoming respiratory virus season, adapted from a popular 1-page summary document prepared by immunize.org.
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.